Epizyme (Nasdaq: EPZM) filed an amended registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The company plans to offer 4,285,000 shares, but has not set an expected price range. The company plans to list on the The Nasdaq Global Market under the symbol “EPZM.”
The offering will be made through Citigroup, Cowen and Company, Leerink Swann, JMP Securities, and Wedbush PacGrow Life Sciences.
Epizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW *NEW – Download StreetInsider’s FREE iPhone and iPad App – Click Here begin ad tag (tile=12) — End ad tag —